Sorafenib is the priority drug used for advanced hepatocellular carcinoma (HCC) [65], as it inhibits the lung metastasis of HCC mediated by CD90+ cancer stem cells (CSCs) [66]. The gene discussed is THY1; the disease is hepatocellular carcinoma.